The Brains Trust-2019, page-323

Re PBT @paddington bear, I thought this company rang a bell and it did, I was invested in it in the early 00s and it is not for me. They are now working in the area of Parkinson’s disease and the drug they are trialling now is a different molecule to the one that failed in 2014 which was for Alzheimer’s. Apparently an increase in iron (presumably linked to Hb) within the cell is linked to Parkinson’s and this new drug targets Fe and removes it. Stage 1 clinical trial with 88 patients underway late last year I believe. That’s about all I can say PB